A Phase 1/2 interventional study of Transdermal patch estradiol and Transdermal patch placebo in Major Depressive Disorder and Postpartum Depression, sponsored by Vibe G Frøkjær, MD, PhD. Recruiting at 1 site in Denmark. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by Vibe G Frøkjær, MD, PhD · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Depressive Disorder, Major with a site in Denmark — 10 open to participants now, 11 under way, none of them phase 3. Depressive Disorder, Major · Denmark.
Among the 44 studies in Depressive Disorder, Major with a site in Denmark, this one is the 6th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 1/2, reaches primary completion later than 2 of the 10 other live ones, and was the 28th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →10 of the 44 studies in Depressive Disorder, Major with a site in Denmark are open now. Recruiting first, the newest first:
Anders Jørgensen · Sites in Denmark
Ages 18+
Aalborg University Hospital · Sites in Denmark
Ages 18–65
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Sites in Denmark
Ages 18–60
Nordsjaellands Hospital · Sites in Denmark
Ages 18–65
University Medical Center Groningen · Sites in Denmark, Czechia, Netherlands and 1 more country
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 80 across the 36 interventional studies, 78 across the 8 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 44 have an industry lead sponsor. The 10 most frequent:
Vibe G Frøkjær, MD, PhD is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Vibe G Frøkjær, MD, PhD has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
7 of the studies in Depressive Disorder, Major with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05616559Rigshospitalet, DenmarkPrecision Medicine in the Depression Treatment | 2026-12 |
| NCT04685148Vibe G Frøkjær, MD, PhDMaternal Mental Health Trial | 2026-12-31 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT07263321Aalborg University HospitalImproving Treatment for Depression in General Practice Using a Step-by-Step Care Plan. | 2027-06 |
| NCT05680220Klaus Martiny40 Hz Light Neurostimulation for Patients With Depression (FELIX) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 44 studies in Depressive Disorder, Major with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Perinatal depression affects 10-15% of women postpartum and has a recurrence rate of 40%. Women who develop perinatal depression might be particularly susceptible to the rapid and large changes in sex steroid hormones, particularly estradiol, across pregnancy to postpartum. This trial aims 1) to evaluate the preventive effect of transdermal estradiol treatment in the immediate postpartum on depressive episodes in a subgroup of women at high-risk for perinatal depression, and 2) to determine if a set of biomarker gene transcripts can identify this subgroup and thus form the basis for future personalised prevention or treatment.
The MAMA Trial is a double-blind, 1:1 randomised, placebo-controlled trial. The trial involves maternity wards at three university hospitals in the Capital Region of Denmark. Women who are singleton pregnant in the third trimester with a prior history of perinatal depression are eligible to participate. Participants will be randomised to either estradiol patches (200 μg per day) or placebo patches for three weeks starting immediately postpartum.
The primary statistical analysis will be performed based on the intention-to-treat principle. A sample size of 220 will provide the trial with 80% power (alpha 0.05, beta 0.2) to detect a reduction in postpartum depression of 50% and to tolerate a drop-out of around 20%.
Major depressive disorder affects twice as many women as men. Women are at increased risk for depression in life phases, where endogenous sex steroid hormone milieu changes; such as in puberty, during late pregnancy to postpartum and across menopausal transition. This includes a subtype of MDD, perinatal depression (PND) that affects 10-15% of mothers postpartum and has a recurrence rate of 40% in subsequent pregnancies. PND is a disabling disorder that affects the entire family, including development and future health of the infant.
The underlying risk and resilience mechanisms in MDD are far from clear, consequently, current treatment strategies are suboptimal. Women who develop PND might be particularly sensitive to the rapid and large changes in sex steroid hormone milieu, seen in the transition from high levels of sex steroid hormones, in particular estradiol, in pregnancy to low levels in the hormone withdrawal phase postpartum. Thus, PND is most likely has a distinct pathophysiology, which may provide a unique opportunity for protecting mental health by targeted short-term prevention in the immediate postpartum period.
Intriguingly, recent human data has provided direct evidence for sex hormone manipulation to provoke subclinical depressive symptoms in about 12% of healthy volunteers. The phenomenon was linked to changes in estradiol, which were induced by the pharmacological manipulation with a Gonadotrophin Releasing Hormone agonist. Estradiol affects critical domains and key brain regions known to be dysfunctional in women with major depressive disorder. Estradiol sensitivity predisposes to PND, which can be demonstrated at the level of gene transcription in clinical cohorts, and is also directly supported by recent research results. Such peripheral markers of estradiol sensitivity may prove useful in identifying individuals at excess risk for PND, also in their first pregnancy, and thus may help direct preventive efforts for the women who can benefit the most.
Transdermal estradiol emerges as a promising preventive treatment option for the postpartum onset of PND supported by epidemiological, preclinical, and clinical research, robust and rapid response to estradiol in some pilot postpartum depression (PPD) trials with few side effects and minimal breastmilk passage to the infant. Further, transdermal estradiol appears to be effective in preventing clinically significant depressive symptoms among perimenopausal women, which is another group of women in hormonal transition phase.
Previously, a double-blind randomized, controlled trial (RCT) showed effect of treatment with transdermal estradiol on manifest PND. A recent pilot RCT with transdermal estradiol as a candidate treatment for postpartum depression failed to achieve its primary outcome, but notably, did reduce depressive symptoms postpartum compared to placebo.
Rather than treating manifest depressive episodes postpartum, the investigators here propose a different approach: to target, and potentially prevent, early risk mechanisms in the first three weeks postpartum, and to direct this preventive strategy towards women in high risk. This immediate and early postpartum timing corresponds to the peak risk period and covers the peak of hormonal decline postpartum.
This trial aims 1) to evaluate the preventive effect of transdermal estradiol treatment in the immediate postpartum on depressive episodes in a subgroup of women at high risk for Perinatal Depression with postpartum onset, and 2) to determine if a set of biomarker gene transcripts can identify this subgroup and thus form the basis for future personalized prevention or treatment.
Methods The Maternal Mental Health (MAMA) Trial is designed as a double-blind, 1:1 randomized, placebo-controlled superiority trial setting involving maternity wards at three university hospitals in the Capital Region of Denmark.
Women who are singleton pregnant in third trimester with a prior history of perinatal depression (onset before six months postpartum) and aged 18 to 45 years are eligible to participate.
The women will be assessed for eligibility by the midwife or obstetrician when attending antenatal care at the outpatient clinic. Eligible participants who verbally consent to receive more information about the trial will subsequently be contacted by telephone. Written informed consent is obtained before inclusion in the MAMA Trial.
The randomisation will be conducted by the capital region pharmacy. Trial participants, clinical care providers, research assistants, investigators, outcome assessors, and data analysists will all be blinded to allocation.
The investigators calculated that a sample of 2*88 complete cases would provide the trial with 80% power (at a two-sided alpha level of 0.05) to detect a reduction in postpartum depression of 50%. Thus, with a study number of 2*110, the design is considered solid and can tolerate 22% dropouts.
The primary statistical analysis will be performed on basis of the intention-to-treat principle. The investigators will compare data on the primary outcome for the two groups for the superiority of estradiol over placebo with Pearson's chi-squared test.
Secondary outcomes with a continuous distribution will be compared between groups with respect to the mean (Student's t-test) if the distribution is unimodal and symmetric, or to the median if the distribution is unimodal but asymmetric, or otherwise to the ranks of the observations (Mann-Whitney test). A test on the difference in proportions will be used for binary secondary outcomes and a Pearson's chi-squared test will be used for categorical data.
As a sensitivity analysis, we will use an instrumental variable approach to estimate causal treatment effect using randomisation as an instrument.
Ethical considerations The short-term administration of estradiol transdermally is not expected to pose unacceptable or intolerable side-effects, disrupt breastfeeding or pass to the infant in any dosages that may pose a risk to the infant. Should un-expected side effects for mother or infant occur or be suspected, the treatment will be disrupted immediately. When removing the patch, serum concentrations of estradiol return to baseline levels within 24 hours. Participants who develop levels of mental distress or depressive symptoms that approach clinical thresholds will be referred to relevant and timely psychiatric care by a trained clinician. All potentially sensitive personal data will be anonymized. The trial will adhere closely to the Helsinki declaration.
Prospect There is a pressing need to develop a preventive strategy to depressive episodes during pregnancy and childbirth, that is targeted, cheap, short-term, and easy to implement. Such work holds promise to positively affect women's mental health, their families, and importantly, if successful, may also improve long-term outcomes of the infant's physical and mental health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estradiol patches (200 μg per day) 0-3 weeks postpartum.
Drug: Transdermal patch estradiol
Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum
Drug: Transdermal patch placebo
Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
Number of participants with Major Depression Disorder
Clinical diagnosis assessed by DSM-V criteria
Time frame: 0-6 months postpartum
EPDS Depressive symptoms
Edinburgh Postnatal Depression Scale score. Score range: 0-30.
Time frame: 8-10 weeks postpartum
HamD6 Depressive symptoms
Score on the Hamilton 6-item depression scale. Score range 0-22.
Time frame: 8-10 weeks postpartum
Maternal mental wellbeing
WHO-5 Well-Being Index. Score range 0-100. Low score means less well-being.
Time frame: 8-10 weeks postpartum
Maternal anxiety
State Trait Anxiety inventory (STAI) score. Score range 20-80.
Time frame: 8-10 weeks postpartum
Parental stress
Parental Stress Scale. Score range 18-90.
Time frame: 8-10 weeks postpartum
Parental reflective capacity
Parental Reflective Functioning Questionnaire. Score range 12-60.
Time frame: 8-10 weeks postpartum
Parental competences
Parenting Sense of Competence scale. Score range 16-96.
Time frame: 8-10 weeks postpartum
Proportion of women who exclusively breastfeed their infants
Questionnaire developed for the trial. Categorical outcome.
Time frame: 8-10 weeks postpartum
Predictive value of composite gene transcription and DNA methylation marker for estrogen sensitivity
116 a priori defined gene transcripts, which where differentially expressed in third trimester of women who later developed perinatal depression with postpartum onset relative to pregnant women who did not and to other depressed (reference Mehta et al, 2014, Psychological Medicine, Mehta et al. 2018 British Journal of Psychiatry).
Time frame: 8-10 weeks postpartum
Maternal sleep quality
Pittsburgh Sleep Quality Index. Score range 0-21.
Time frame: 8-10 weeks postpartum
Maternal attachment to unborn child
Maternal Antenatal Attachment Scale. Score range 19-95.
Time frame: Baseline time point at third trimester, i.e. week 34-37 of pregnancy
Cold cognitive function
A later variable derived from simple reaction time test, Rey's Auditory Verbal Learning Task (Declarative memory, RAVLT), Letter-Number Sequence (Working Memory, LNS), and Intra-Extra Dimensional Set Shifting (Cognitive flexibility, IED, error rate)
Time frame: 8-10 weeks postpartum
Hot cognitive function
A latent variable derived from emotional Intensity Morphing Test (EIMT) and Infant Emotion Test (Maternal Distress Sensitivity and Infant Emotion Detection (IET)
Time frame: 8-10 weeks postpartum
Socio-emotional infant development
Ages and Stages questionnaire Social-emotional 2 (ASQ:SE-2) total score. Score range 0-160. Higher scores worse outcome.
Time frame: 8-10 weeks
Infant development (Bayley-III)
Cognitive, language and motor development score from Bayley-III test
Time frame: 8-10 weeks postpartum
Cortisol dynamics Cortisol dynamics
Cortisol awakening response in saliva (area under the curve with respect to increase from 0 to 60 minutes from awakening)
Time frame: 3-5 weeks postpartum
Cortisol evening Cortisol dynamics
Cortisol concentration in evening saliva from home sampling
Time frame: 3-5 weeks postpartum
Hair cortisol level Cortisol dynamics
Provides an estimate of cortisol exposure up to 6 months prior to delivery
Time frame: 0-1 days postpartum
Epigenetic markers relevant for infant HPA axis
FKBP5 methylation index
Time frame: 0-1 days postpartum
Estradiol level
Estradiol level in peripheral blood
Time frame: 3 weeks postpartum
Change in estradiol level
Estradiol change pre- to postpartum in peripheral blood
Time frame: From baseline (third trimester of pregnancy) to 3 weeks postpartum
Progesterone level
Progesterone level in peripheral blood
Time frame: 3 weeks postpartum
Change in progesterone level
Progesterone change pre- to postpartum in peripheral blood
Time frame: From baseline (third trimester of pregnancy) to 3 weeks postpartum
Allopregnanolone level
Allopregnanolone level in peripheral blood
Time frame: Baseline time point at third trimester, i.e. week 34-37 of pregnancy
Allopregnanolone level
Allopregnanolone level in peripheral blood
Time frame: 3 weeks postpartum
Change in allopregnanolone level
Allopregnanolone change pre- to postpartum in peripheral blood
Time frame: From baseline (third trimester of pregnancy) to 3 weeks postpartum
Negative bias in responses to infant vocalisations and video
Composite measure of negative bias score of ratings of 50 infant vocalisations and negative emotional expression.
Time frame: 8-10 weeks
Estradiol level
Estradiol level in peripheral blood
Time frame: Baseline time point at third trimester, i.e. week 34-37 of pregnancy
Plan to share: Yes — When the planned analyses from the trial are published, the data will become publicly available. According to the Danish legislation, data will be available only by approval by the Danish Data Protection Agency and with a signed agreement.
Supporting information: Study protocol
Time frame: We expected that data will come available December 2026 and be available for approx. 4 years.
Access criteria: Data will be available on reasonable request with approval by the Danish Data Protection Agency and with a signed agreement.
Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.
Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's planned 70 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vibe G Frøkjær, MD, PhD